Company Profile

Regis Technologies Inc
Profile last edited on: 3/9/2022      CAGE: 31ZF3      UEI: CXP2QC5SGSM6

Business Identifier: Provides process and analytical development of small molecule APIs for pharma companies.
Year Founded
1956
First Award
1998
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8210 Austin Avenue
Morton Grove, IL 60053
   (847) 967-6000
   cservice@registech.com
   www.registech.com
Location: Single
Congr. District: 09
County: Cook

Public Profile

Long time established with 100+ employees on staff, Regis Technologies, Inc. functions as a partner in the development, scale-up, and manufacture of complex, multi-step custom synthetic products for clients in the pharmaceutical, diagnostic, and biotech industries. Matching the firm's extensive organic expertise to collegiate collaborations, a number of innovative chromatography products, especially those with a chiral emphasis, have been formed. The firm's proficiency in synthetics and chromatographic capabilities has enabled the firm to offer a preparative separation service designed for the resolution of compounds on a gram to kilogram scale.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $250,702
Project Title: Cellular membrane affinity chromatography kit for drug discovery
1998 1 NIH $99,953
Project Title: Microscale Synthesis And Evaluation Of Csp Libraries

Key People / Management

  Louis Glunz -- President

  Lukasz Michal Ciesla

  Burr Martin -- CFO, COO

  Christopher J Welch

Company News

There are no news available.